Therapeutic processes and useful compositions therefor

Details Therapeutic processes and useful compositions therefor Therapeutic processes and useful compositions therefor

2003-12-08

2009-10-27

Mosher, Mary E (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S189100

Reexamination Certificate

active

07608274

ABSTRACT:
This invention provides novel processes for therapeutic applications, including the treatment of subjects carrying infectious agents or having impaired autoimmunity or impaired immune condition. The therapeutic applications disclosed herein are also directed at the treatment of cancerous subjects with malignant tumors containing cancerous cells or malignant or cancerous cells. Vaccination processes for preventing infections in subjects are also provided. The novel processes comprise introducing into or administering to a subject one or more antigens, or trained or adopted immune cells. These antigens or immune cells are capable of establishing or increasing at least one first specific immune response and decreasing at least one second specific immune response. Such responses include components, such as cellular immune reaction elements, humoral immune reaction elements and cytokines, the latter also encompassing interferons and lymphokines. Useful compositions are also provided by this invention.

REFERENCES:
patent: 5272065 (1993-12-01), Inouye et al.
patent: 5861158 (1999-01-01), Kwak et al.
patent: 5958681 (1999-09-01), Wetmur et al.
patent: 6297048 (2001-10-01), Jolly et al.
patent: 2001/0007153 (2001-07-01), Brown et al.
patent: 2004/0022768 (2004-02-01), Roy-Chowdhury et al.
patent: 2005/0118196 (2005-06-01), Ilan et al.
patent: 2005/0136074 (2005-06-01), Ilan et al.
patent: 2005/0147586 (2005-07-01), Ilan et al.
patent: 2005/0255454 (2005-11-01), Ilan et al.
patent: 2005/0260227 (2005-11-01), Ilan et al.
patent: 2005/0260560 (2005-11-01), Ilan et al.
patent: 2005/0277112 (2005-12-01), Ilan et al.
patent: 1072271 (2000-07-01), None
Saldinger et al (Gastroenterology 115:891-897).
Ilan et al (Medical Hypotheses 52:505-509, 1999, in IDS).
Ilan et al (Hepatology 27:1368-1376, May 1998).
Gotsman et al (Gastroenterology 116:A1216-1217, 1999, in IDS).
Czerkinsky et al (Immunological Reviews 170:197-222, 1999).
Challacombe et al (Journal of Experimental Medicine 152:1459-1472, 1980).
Benjamini, E., et al, editors,Immunology: a Short Course, Wiley-Liss, New York (1991).
Chisari, et al, “Hepatitis B virus immunopathogenesis,”Ann. Rev. Immunol. 13:29-60.
Guidotti, et al, “Viral clearance without destruction of infected cells during acute HBV infection,”Science 284:825-829 (1999).
Hauer, et al, “An analysis of interferon gamma, IL4, IL-5 and IL-10 production by ELISPOT and quantitative reverse transcriptase-PCR in human Peyer's patches,”Cytokine 10:627-634 (1998).
Hollinger, et al, “Improved double antibody radioimmunoassay (RIA-D) methodology for detecting hepatitis B antigen and antibody,” (Abstract only)Am. Soc. Microbiol. 72:213 (1972).
Ilan, et al, “Insertion of the Adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long term gene expression,”Proc. Natl. Acad. Sci. USA 94:2587-2592 (1997).
Ilan, et al, “Oral tolerization to adenoviral antigens permits long term gene expression using recombinant adenoviral vectors,”J. Clin. Invest. 99:966-973 (2000).
Ilan, et al, “Treatment of experimental colitis by oral tolerance induction: a central role for suppressor lymphocytes,”Am. J. Gastroenterol. 95:966-973 (2000).
Ishikawa, et al, “Polyclonality and multispecificity of the CTL response to a single viral epitope,”J. Immunol. 161:5842-5850 (1998).
Larsson, et al, “A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals,”AIDS 13:767-777 (1999).
Rehermann, et al, “Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatits B virus infection,”J. Clin. Invest. 7:1655-1665 (1996).
Shouval, et al, “Comparative morphology and tumorigenicity of human hepatocellular cell carcinoma lines in athymic rats and mice,”Vichow's Archives A. Path. His. 412:595-606.
Shouval, et al, “Adoptive transfer of immunity to hepatitis B virus in mice following bone marrow transplantation through immunization of bone marrow donors,”Hepatology 17:955-959 (1993).
Sigal, LH, et al,Immunology and Inflammation: Basic Mechanisms and Clinical Consequences, McGraw Hill, New York, p. 528 (1994).
Stites, DP, et al,Basic and Clinical Immunology, Appleton & Lange, Norwalk, CT (1991).
Weiner, HL, et al, editors, “Oral Tolerance: Mechanisms and Applications,”Annals of the New York Academy of Sciences 778(1996).
Bretscher, et al, “Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states,” (Abstract only)Behring Inst. Mitt. 98:153-159 (1997).
Ahuja, S.S., et al., “Human Dendritic Cell (DC)-Based Anti-Infective Therapy: Engineering DCs to Secrete Functional IFN-y and IL-12,”J. Immunol. 161:868-876 (1998).
Chow, Y-H, et al., “Development of Th1 and Th2 Populations and the Nature of Immune Response to Hepatitis B Virus DNA Vaccines Can be Modulated by Codelivery of Various Cytokine Genes,”J. Immunol. 160:1320-1329 (1998).
Ribas, A., et al., “Immune Deviation and Fas-mediated Deletion Limit Antitumor Activity after Multiple Dendritic Cell Vaccinations in Mice,”Cancer Research 60:2218-2224 (2000).
Waris, M.E., et al., “Respiratory Syncytial Virus Infection in BALB/c Mice Previously Immunized with Formalin-Inactivated Virus Induces Enhanced Pulmonary Inflammatory Response with a Predominant Th2-Like Cytokine Pattern,”J. Virology 70:2852-2860 (1996).
Gotsman, I., et al., “Oral Tolerance Towards Hepatitis B Antigens in a Murine Model,”Gastroenterology 116:A1216-A1217 (1999).
Gotsman, I., et al., “Induction of Oral Immune-Regulation Towards Hepatitis B Virus Envelope Proteins Suppresses the Growth of Hepatocellular Carcinoma in Mice,”Hepatology 32:206A (2000).
Gotsman, I., et al., “Induction of oral tolerance towards hepatitis B envelope antigens in a murine model,”Antiviral Research 48:17-26 (2000).
Gotsman, I., et al., “Downregulation of a tumor promotion immune response via induction of oral tolerance towards tumor-associated-antigens: can we ‘eat the tumor?’,”Medical Hypotheses 56:487-492 (2001).
Ilan, Y., et al., “Induction of tolerance to hepatitis B virus: can we ‘eat the disease’ and live with the virus?,”Medical Hypotheses 52:505-509 (1999).
Ilan, Y., et al., “Induction of oral Tolerance in splenocyte recipients toward pretransplant antigens ameliorates chronic graft versus host disease in a murine model,”Blood 95:3613-3619 (2000).
Nagler, A., et al., “Oral Tolerization Ameliorates Liver Disorders Associated with Chronic Graft Versus Host Disease,”Hepatology 28:403A (1998).
Safadi, R., et al., “Oral Immune-Regulation Towards Hepatitis B Virus Proteins. A New Mode of Treatment for Chronic HBV Infection: Results of a Phase 1 Clinical Trial,”Hepatology 32:379A (2000).
Saldinger et al., Immunization of BALB/C Mice With Helicobacter Urease B Induces A T Helper 2 Response Absent . . . Gastroenterology 1998;115:891-897.
Ilan et al., Oral Tolerization to Adenoviral Proteins Permits Repeated Adenovirus-Mediated Gene Therapyin Rats . . . Hepatology 1998;27:1368-1376.
Diepolder et al., Anergic TH1 Clones Specific for Hepatitis B Virus (HBV) Core Peptides . . . J. of Virology 1996, vol. 70, No. 11, pp. 7540-7548.
Furuta et al., Clinicopathologic Features of Hepatocellular Carcinoma in Young Patients, Cancer 1990, 66: 2395-2398.
Ilan et al., Induction of Tolerance to Hepatitis B Virus: Can We ‘Eat the Disease’ and Live With the Virus, Medical Hypotheses 1999; 52(6): 505-509.
Safadi et al., Induction of Oral Immune Regulation Towards Liver-Extracted Proteins for Treatment of Chronic HBV and . . . Liver International 2004; 24:295-3

Affiliated with

Also associated with

Rating

Therapeutic processes and useful compositions therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic processes and useful compositions therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic processes and useful compositions therefor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4058007